Firm will close three recently-acquired US sites and shift operations to the growing pharmaceutical hub in Massachusetts
Japanese pharma firm Takeda plans to close three US sites and move the headquarters of its vaccines business unit to the growing pharmaceutical hub in the Boston and Cambridge area of Massachusetts. The company has not disclosed its plans for the staff at the sites set to close.
Over the next two years, Takeda will close the site that belonged to LigoCyte Pharmaceuticals in Bozeman, Montana, which it acquired in 2012; as well as former Inviragen sites in Madison, Wisconsin and Fort Collins, Colorado, acquired in 2013. Vaccine activities from Takeda’s site in Deerfield, Illinois – currently designated as the global headquarters of the firm’s vaccine activities – will move to Boston by mid-2017.
The move is part of a growing trend of consolidation in the Boston–Cambridge and south San Francisco areas within the pharmaceutical and biotechnology industries. Amgen, for example, is in the middle of a programme to cut around 3000 jobs, and concentrating its presence in these areas.